Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of extensive-stage small cell lung cancer
• No untreated brain metastases
• * No active symptoms related to brain metastases
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Hemoglobin ≥ 9.0 g/dL
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement)
• Creatinine ≤ 1.5 times ULN
• INR \< 1.5 or PT/PTT normal
• No history of cardiac disease, including any of the following:
• * NYHA class III-IV congestive heart failure
• * Unstable angina (i.e., anginal symptoms at rest)
• * Onset of angina within the past 3 months
• * Myocardial infarction within the past 6 months
• No cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
• No uncontrolled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg or diastolic BP \> 90 mm Hg, despite optimal medical management
• No thrombolic or embolic events, such as cerebrovascular accident or transient ischemic attacks, within the past 6 months
• No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within the past 4 weeks
• No other hemorrhage/bleeding event ≥ CTCAE grade 3 within the past 4 weeks
• No known HIV infection or chronic hepatitis B or C infection
• No active clinically serious infection \> CTCAE grade 2
• No serious non-healing wound, ulcer, or bone fracture
• No evidence or history of bleeding diathesis or coagulopathy
• No significant traumatic injury within the past 4 weeks
• No known or suspected allergy to sorafenib tosylate or to any other drug given during the study
• No condition that would impair the patient's ability to swallow whole pills
• No known malabsorption problem
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception
• * Male patients must use effective contraception during and for ≥ 3 months after completion of sorafenib tosylate
• PRIOR CONCURRENT THERAPY:
• Prior radiotherapy to the brain allowed
• No prior chemotherapy
• More than 4 weeks since prior major surgery or open biopsy
• No concurrent Hypericum perforatum (St. John's wort) or rifampin
• Concurrent anti-coagulation treatment, such as warfarin or heparin, allowed